Valuation: HighTide Therapeutics, Inc.

Market Cap 1.23B 1.43B 182M 160M 149M 137M 257M 17.44B 263M 1.77B 693M 8.63B 684M 669M 29.84B P/E 2024
-1.41x
P/E 2025 -5.19x
Enterprise Value 857M 993M 127M 111M 104M 95.28M 178M 12.12B 183M 1.23B 481M 6B 475M 465M 20.74B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
44.17%
Yield 2024 *
-
Yield 2025 -
1 day-3.10%
1 week-4.94%
Current month-6.72%
1 month-7.06%
3 months-33.16%
6 months-9.42%
Current year-15.25%
1 week 2.47
Extreme 2.47
2.94
1 month 2.32
Extreme 2.32
3.01
Current year 1.8
Extreme 1.8
4.72
1 year 1.8
Extreme 1.8
4.72
3 years 0.72
Extreme 0.72
13.18
5 years 0.72
Extreme 0.72
13.18
10 years 0.72
Extreme 0.72
13.18
Manager TitleAgeSince
Chief Executive Officer 56 01/01/2011
Director of Finance/CFO 57 01/12/2022
Chief Tech/Sci/R&D Officer - 02/02/2026
Director TitleAgeSince
Director/Board Member 68 30/11/2020
Director/Board Member 61 -
Chairman 56 -
Date Insider Type Main position Quantity % Market Cap.
30/4/26 Other

Director

1,800,000 0.3151%
1/4/26 Other

Chief Executive Officer

8,325,618 1.4572%
1/4/25 Other

Chief Executive Officer

3,960,550 0.7694%
Change 5-day change 1-year change 3-year change Capi.($)
-3.10%-4.94%-27.11% - 188M
+0.47%+2.03%+51.54%+70.84% 55.01B
+2.83%+0.04%+38.07%+82.59% 54.24B
+0.54%+0.67%-17.59%-13.47% 23.38B
-0.97%-5.06%+1.35%+383.00% 22.57B
+2.07%+1.44%+23.06%-9.05% 20.19B
-2.15%+0.78%+24.67%-31.03% 17.86B
-2.14%-2.72%+30.26%+536.72% 15.5B
-3.14%-8.09%+160.68%+292.18% 14.2B
-2.09%-1.41%+24.65%+178.74% 14.2B
Average -0.74%-1.97%+30.96%+165.61% 23.73B
Weighted average by Cap. +0.30%-0.76%+35.90%+130.62%

Financials

2024 2025
Net sales - -
Net income -382M -442M -56.39M -49.55M -46.25M -42.44M -79.45M -5.4B -81.41M -548M -214M -2.67B -212M -207M -9.24B -245M -284M -36.18M -31.79M -29.67M -27.23M -50.98M -3.47B -52.24M -352M -138M -1.71B -136M -133M -5.93B
Net Debt -413M -478M -60.97M -53.57M -50M -45.89M -85.9M -5.84B -88.02M -593M -232M -2.89B -229M -224M -9.99B -376M -435M -55.53M -48.79M -45.54M -41.8M -78.24M -5.32B -80.17M -540M -211M -2.63B -208M -204M -9.1B
Logo HighTide Therapeutics, Inc.
HighTide Therapeutics Inc is a biopharmaceutical company specializing in the discovery, development and commercialization of multifunctional, multi-targeted therapies for the treatment of metabolic and digestive diseases. The Company has developed a product pipeline of multiple product candidates in-house, covering many indications in metabolic and digestive diseases among which, some are at clinical-stage. The Company’s core product, HTD1801 (berberine ursodeoxycholate), a new molecular entity, is a gut-liver anti-inflammatory metabolic modulator which targets multiple pathways pivotal to metabolic regulation, including those associated with metabolic and digestive diseases. The Company conducts operations in the United States, Mainland China, Hong Kong and Australia.
Employees
51
Date Price Change Volume
29/07/26 HKD 2.500 -3.10% 132,616
28/07/26 HKD 2.580 -2.64% 116,000
27/07/26 HKD 2.650 0.00% 25,000
24/07/26 HKD 2.650 -1.12% 67,000
23/07/26 HKD 2.680 +3.88% 185,500

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 2511 Stock